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ABSTRACT
The anaplastic lymphoma kinase (ALK) gene is overexpressed, mutated or 
amplified in most neuroblastoma (NB), a pediatric neural crest-derived embryonal 
tumor. The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to 
NB tumorigenesis in mouse models, and cooperate with MYCN in the oncogenic process. 
However, the precise role of activating ALK mutations or ALK-wt overexpression in 
NB tumor initiation needs further clarification. 
Human ALK-wt, ALK-F1174L, or ALK-R1275Q were stably expressed in murine 
neural crest progenitor cells (NCPC), MONC-1 or JoMa1, immortalized with v-Myc or 
Tamoxifen-inducible Myc-ERT, respectively. While orthotopic implantations of MONC-
1 parental cells in nude mice generated various tumor types, such as NB, osteo/
chondrosarcoma, and undifferentiated tumors, due to v-Myc oncogenic activity, 
MONC-1-ALK-F1174L cells only produced undifferentiated tumors. Furthermore, our 
data represent the first demonstration of ALK-wt transforming capacity, as ALK-
wt expression in JoMa1 cells, likewise ALK-F1174L, or ALK-R1275Q, in absence of 
exogenous Myc-ERT activity, was sufficient to induce the formation of aggressive and 
undifferentiated neural crest cell-derived tumors, but not to drive NB development. 
Interestingly, JoMa1-ALK tumors and their derived cell lines upregulated Myc 
endogenous expression, resulting from ALK activation, and both ALK and Myc activities 
were necessary to confer tumorigenic properties on tumor-derived JoMa1 cells in 
vitro.
INTRODUCTION
Neuroblastoma (NB) is a heterogeneous childhood 
malignancy from embryonic origin arising from neural 
crest progenitor cells (NCPC) of the sympathoadrenal 
lineage [1]. Neural crest (NC) is a transient highly 
migratory population of neuroectodermal pluripotent 
stem cells in vertebrate embryo. NC cells from the trunk 
migrate and differentiate to give rise to glia, neurons of 
the dorsal root ganglia, Schwann cells, melanocytes, and 
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adrenal medulla [2-4]. NB is believed to originate from a 
subset of these migratory NC derivatives committed to the 
sympathoadrenal lineage, which differentiate into adrenal 
chromaffin cells or sympathetic ganglia [1, 4]. 
The anaplastic lymphoma kinase (ALK) gene 
belongs to the insulin receptor superfamily of receptor 
tyrosine kinase (RTK). ALK has been recently extensively 
studied as a candidate in the development of new targeted 
treatments for progressive and resistant NB. ALK is 
expressed in the developing central and peripheral nervous 
system during embryogenesis [5], and in the developing 
sympathoadrenal lineage of the NC, where its signaling 
may regulate the balance between cell proliferation and 
differentiation [1, 6, 7]. ALK physiological role in the 
normal development of the nervous system is not yet fully 
understood, but ALK having a role in neurogenesis control 
was demonstrated in Drosophila, zebrafish, and chicken 
[6, 8, 9].
ALK mutations were described in ~10 % of NB 
cases, copy number gain in ~15%, and ALK amplification 
in 2-4 % of NB [1, 10-16]. Furthermore, overexpression 
of ALK-wt or mutated receptors was detected in the 
majority of NB, and was shown to be associated with 
poor clinical outcome [17, 18]. The two most frequent 
mutations F1174L (only present in sporadic NB) and 
R1275Q (in sporadic and familial NB) correspond to 
34.7% and 49% of mutated ALK, respectively [10, 15, 
19]. Both mutations lead to ALK constitutive activation 
by autophosphorylation, although ALK-F1174L displays 
a higher degree of phosphorylation, and an increased 
tumorigenic potential compared to other ALK mutations 
[10, 13, 20-22, 26]. Both activating mutations, ALK-
F1174L and ALK-R1275Q, were also shown to contribute 
to NB tumorigenesis in transgenic and knock-in (KI) 
animal models, as well as to cooperate with MYCN in 
the oncogenic process [23-26]. In patient, although 
association of ALK-F1174 hotspot mutations with MYCN 
amplification is still under debate [10, 11], co-occurrence 
of both genetic alterations lead to very poor outcome 
compared to single defect. 
To date, the role of activating ALK mutations or 
ALK-wt overexpression in NB tumor initiation and 
progression remains unclear. Indeed, although germline 
activating ALK mutations occur in 80% of familial 
NB, they display incomplete penetrance suggesting 
that additional genetic alterations may be required for 
NB initiation [15, 16, 27]. Moreover, ALK-F1174L 
expression, in mouse and zebrafish transgenic NB models, 
as well as in KI model, was not sufficient to initiate NB 
tumor formation in absence of MYCN co-expression or 
additional genetic alterations syntenic to that commonly 
found in human NB [23-25, 26]. This suggests that ALK-
F1174L, similarly to germline ALK mutations, required 
secondary hits to drive NB formation [23].
In this study, we investigated the ability of ALK-wt, 
and the most common activating mutations, ALK-F1174L 
and ALK-R1275Q, to initiate tumor formation in NCPC, 
and we compared their in vivo oncogenic potential. In 
this aim, two murine NCPC models were selected, the 
MONC-1 cell line immortalized with v-Myc [28], and the 
JoMa1 cell line expressing a Tamoxifen-inducible Myc-
ERT [29], allowing evaluation of ALK-wt and variant 
functions in presence or absence of exogenous Myc 
activity. Stable expression of ALK-wt or gain-of-function 
mutants in NCPC were sufficient to induce formation of 
highly aggressive and undifferentiated tumors, but not to 
drive NB tumor progression. Moreover, Myc endogenous 
expression was strongly upregulated in orthotopic JoMa1-
ALK tumors or their derived cell lines as a result of ALK 
activation, and both ALK and Myc activities were required 
to maintain in vitro tumorigenic capacities of tumor-
derived cell lines. These data strongly support a role for 
ALK-wt, in addition to ALK-F1174L and ALK-R1275Q, 
to confer in vitro and in vivo tumorigenic properties on 
NCPC.
RESULTS
ALK-F1174L expression in murine NCPC 
MONC-1 impairs differentiation of NC cell-
derived tumors.
To investigate the oncogenic potential of ALK-
F1174L mutation in NCPC, human ALK-F1174L was 
overexpressed in the murine NCP cell line, MONC-1, 
previously immortalized by stable v-Myc expression [28] 
(Figure 1A). Transduced MONC-1 cells conserved their 
NCPC phenotype, as the NC stem cell (NCSC) markers, 
except Sox10, were still expressed, while glial or neuronal 
differentiation markers were not detected (Supplementary 
Figure 1A). The tumorigenic potential of MONC-1-ALK-
F1174L or parental MONC-1 cells was analyzed in vivo 
by orthotopic implantation into nude mice adrenal glands 
(AG). Interestingly, mice implanted with MONC-1-ALK-
F1174L cells developed highly aggressive tumors in 
all mice (10/10, 100%) within three weeks, while mice 
engrafted with parental MONC-1 cells developed tumors 
in AG with a significantly longer latency (7/9, 78%)
(Figure 1B). MONC-1-ALK-F1174L-derived tumors 
strongly expressed human ALK mRNA and protein as 
expected, but not murine Alk (Supplementary Figure 1B). 
Thus, ALK-F1174L strongly accelerated MONC-1 cell-
derived tumor growth. 
All mice implanted with MONC-1-ALK-F1174L 
cells developed highly malignant undifferentiated 
tumors, as they strongly expressed the mesechymal/
stem marker CD44 and the neural stem/progenitor cell 
marker nestin, but did not stain for the neuronal marker 
Ncam1, the adrenergic differentiation marker tyrosine 
hydroxylase (Th), and the sympathoadrenal marker 
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Phox2b, recently demonstrated as a highly specific marker 
of undifferentiated NB [30] (Figure 1C). In contrast, 
MONC-1 cells gave rise to various tumor types, as 3/7 
mice developed osteosarcoma with chondrosarcoma 
components (Figure 1D), 1/7 mouse developed a highly 
malignant Phox2b-/nestin+ undifferentiated tumor 
(Figure 1E), and 3/7 mice developed Phox2b+/Th-/nestin- 
undifferentiated NB (Figure 1F). The three MONC-1-
derived NB tumors displayed features of unfavorable NB 
as seen in patients, such as stroma poor and high MKI 
(data not shown). These NB tumors expressed reduced 
levels of CD44, but increased levels of Ncam1, compared 
to undifferentiated tumors derived either from MONC-1 
or MONC-1-ALK-F1174L cells (Figure 1C, E, and F). 
Altogether, these results suggest that v-Myc, constitutively 
expressed in MONC-1 cells, enables the formation of 
diverse differentiated tumors corresponding to various 
NCPC derivates. Moreover, ALK-F1174L expression is 
highly tumorigenic in MONC-1 cells, and seems to impair 
NCPC differentiation, as MONC-1-ALK-F1174L cells 
only produced highly undifferentiated NC cell-derived 
tumors.
Figure 1: ALK-F1174L impairs differentiation of MONC-1-derived tumors. A. Whole cell extract of MONC-1 parental 
cells and MONC-1-ALK-F1174L transduced cells were analyzed by immunoblotting for the presence of human ALK. β-actin was used as 
loading control. B. Tumor take (number of tumor-bearing mice /total nude mice) and growth (mean tumor volumes ± SEM) of MONC-1 
and MONC-1-ALK-F cells orthotopically implanted and measured by echography (unpaired t test with Welch’s correction, ***=p<0.0001). 
C. H&E and IHC analyses for various markers are shown for one representative tumor derived from MONC-1-ALK-F1174L cells 
(magnification 40x, scale = 20 µm). Positive controls for Th (ganglion), Phox2b (NB), and for Ncam1 (adrenal gland) are shown in small 
inserts. D. H&E analysis of one representative osteosarcoma tumor with chondrodarcoma componant derived from MONC-1 cells (left: 
osteosarcoma, right: chondrosarcoma). E. The undifferentiated tumor derived from MONC-1 cells is shown. F. One representative NB 
tumor derived from MONC-1 cells is shown.
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JoMa1 cells expressing ALK-wt, ALK-F1174L, or 
ALK-R1275Q are tumorigenic in vivo. 
We next addressed the oncogenic potential of ALK-
wt and ALK-R1275Q mutation, as compared to ALK-
F1174L variant, in NCPC in absence of v-Myc oncogene 
expression. For this purpose we used the murine NCP cell 
line, JoMa1, expressing Tamoxifen (4-OHT)-inducible 
Myc-ERT [29]. Human ALK-wt, ALK-F1174L, and ALK-
R1275Q variants were stably overexpressed in JoMa1 
cells, while endogenous murine Alk was undetectable in 
these cells (Figure 2A). NCPC phenotype of transduced 
JoMa1 cells was not affected by retroviral infections and 
ALK expression. Indeed, except for Sox10 expression 
which was undetectable in JoMa1-ALK-R1275Q cells, 
transduced cells still expressed the NCSC markers 
Figure 2: ALK-wt-, ALK-F1174L-, and ALK-R1275Q-expressing JoMa1 cells are tumorigenic in subcutaneous in vivo 
model. A. Analyses of ALK mRNA and protein expressions in parental JoMa1 cells and in JoMa1 cells transduced with the empty vector 
(Migr) or vector encoding for ALF-wt, ALK-F1174L or ALK-R1275Q. Murine GAPDH and β-actin were used as control for RT-PCR 
(top) or immunoblotting (bottom), respectively. B. Expression levels of various NCSC and differentiation markers analyzed by RT-PCR 
in total RNA from JoMa1 parental and transduced cells. C. Immunoblotting analysis of ALK phosphorylation in transduced JoMa1 cells. 
β-actin was used as loading control. D. Tumor take (number of tumors/total implanted mouse flanks) and growth (mean tumor volumes 
± SEM) of JoMa1 parental and transduced cells implanted subcutaneously in both flanks of nude mice are represented (one way Anova 
*=p<0.05, **=p<0.005) E. H&E, and IHC-staining for ALK of one representative subcutaneous tumor derived from JoMAa1-ALK-wt, 
-ALK-F1174L, and -ALK-R1275Q cells (magnification 40x, scale = 20 µm).
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Figure 3: In vivo orthotopic implantations of ALK-wt, ALK-F1174L, and ALK-R1275Q cells generate undifferentiated 
NC cell-derived tumors. A. Kaplan-Meier survival curves of orthotopically engrafted mice. Orthotopic tumor growth was followed 
by echography and mice were sacrificed once tumor on left AG reached approximately 800 mm3: JoMa1-ALK-F1174L, JoMa1-ALK-
R1275Q, and JoMa1-ALK-wt group of mice were sacrificed from 24 to 35, 44 to 59, and 52 to 73 days post-injection, respectively (Gehan-
Breslow-Wilcoxon test). All remaining mice were sacrificed 3 months post-injection. B. H&E and IHC staining for ALK and Ki67 of one 
representative orthotopic tumor of JoMa1-ALK-wt, -ALK-F1174L, and -ALK-R1275Q groups (magnification 40x, scale = 20 µm). C. IHC 
of various markers in one orthotopic JoMa1-ALK-F1174L tumor representative of all subcutaneous and orthotopic tumors (magnification 
40x, scale = 20 µm). Positive controls for Th (ganglion), Phox2b (NB), CD99 (islet of Langerhans), Tyr (melanoma), and Ptprc (CD45) 
(spleen) are shown in small inserts. D. Bare graph showing expression levels of different genes in JoMa1-ALK tumors, NB murine 
transgenic model, JoMa1 cell lines, and adrenal glands.
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Ngfr, Sox9, Snai1, and Snai2, while glial, or neuronal 
differentiation markers were not detected (Figure 2B). 
Sustained ALK activation was detected by immunoblotting 
in JoMa1-ALK expressing cells (Figure 2C). 
The in vivo tumorigenic potential of JoMa1-ALK-
F1174L, -ALK-R1275Q, and -ALK-wt cells was then 
assessed after subcutaneous engraftment in absence of 
4-OHT, thus without Myc-ERT activation. Interestingly, 
JoMa1-ALK-wt cells were able to drive tumor formation, 
likewise JoMa1-ALK-R1275Q, and JoMa1-ALK-F1174L 
cells, while JoMa1-Migr and JoMa1 control cells did not 
induce tumor development (Figure 2D). ALK-F1174L 
conferred an enhanced tumorigenic potential to JoMa1 
cells when compared to ALK-R1275Q and ALK-wt 
(Figure 2D). Human exogenous ALK expression in 
JoMa1-derived subcutaneous tumors was confirmed by 
IHC and RT-PCR analyses, while murine Alk mRNA 
was undetected (Figure 2E and Supplementary Figure 2). 
Thus, in absence of any exogenous Myc activation, ALK-
wt or ALK activating mutations displayed transforming 
Table 1: Selected neural crest and stem cells associated markers upregulated (left), and sympathoadrenal lineage, 
neuronal, and neuroendocrine markers downregulated (right) in JoMa1-ALK-derived tumors compared to transgenic 
NB models. 
Genes upregulated in JoMa1-ALK-derived tumors Genes downregulated in JoMa1-ALK-derived tumors
Gene 
Symbol Gene Name
Fold 
Change
Gene 
Symbol Gene Name
Fold 
Change
Hmga2 high mobility group AT-hook 2 2720.3 Meis1 Meis homeobox 1 -3.0
Mmp9 matrix metallopeptidase 9 158.4 Ncam1 neural cell adhesion molecule 1 -5.6
Myc myelocytomatosis oncogene 151.1 Uchl1 ubiquitin carboxy-terminal hydrolase L1 -10.1
Snai2 snail homolog 2 (Drosophila) 59.5 Nefl neurofilament, light polypeptide -11.9
Gja1 gap junction protein, alpha 1 58.9 Mycn
v-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived 
(avian)
-16.0
Twist2 twist homolog 2 (Drosophila) 52.4 Gata2 GATA binding protein 2 -22.7
Twist1 twist homolog 1 (Drosophila) 41.5 Syp synaptophysin -30.4
Nes nestin 39.4 Ret ret proto-oncogene -43.8
Junb Jun-B oncogene 34.0 Alk anaplastic lymphoma kinase -72.7
Bmp2 bone morphogenetic protein 2 29.4 Mdk midkine -98.3
Wnt7b wingless-related MMTV integration site 7B 28.2 Nefh neurofilament, heavy polypeptide -114.0
Pax3 paired box gene 3 27.6 Gata3 GATA binding protein 3 -188.9
Pdgfa platelet derived growth factor, alpha 25.3 Dbh dopamine beta hydroxylase -216.8
Hoxb2 homeobox B2 25.0 Phox2a paired-like homeobox 2a -230.1
Klf4 Kruppel-like factor 4 (gut) 24.5 Phox2b paired-like homeobox 2b -292.5
Cd44 CD44 antigen 22.3 Chga chromogranin A -376.7
Met met proto-oncogene 21.2 Nefm neurofilament, medium polypeptide -600.7
Cd34 CD34 antigen 19.0 Th tyrosine hydroxylase -1221.0
Sox9 Gene Name 18.9 Chgb chromogranin B -1301.9
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 15.9 Ddc dopa decarboxylase -3205.6
Bmp1 bone morphogenetic protein 1 12.6 Bex1 brain expressed gene 1 -4031.5
Fgfr1 fibroblast growth factor receptor 1 12.6
Notch2 Notch gene homolog 2 (Drosophila) 11.5
Sox2 SRY-box containing gene 2 8.7
Vim vimentin 3.5
Hif1a hypoxia inducible factor 1, alpha subunit 2.9
Notch1 Notch gene homolog 1 (Drosophila) 2.7
Pdgfb platelet derived growth factor, B polypeptide 2.4
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capacities in NCPC.
JoMa1-ALK-wt, -ALK-F1174L, and -ALK-
R1275Q cells generate undifferentiated NC cell-
derived tumors in vivo upregulating NCSC or SC 
associated markers
Orthotopic implantations were then performed in 
order to faithfully reproduce NB tumor microenvironment. 
As observed in subcutaneous implantations, JoMa1-ALK 
expressing cells rapidly induced tumor formation, and 
mice engrafted with JoMa1-ALK-F1174L cells developed 
tumors in AG much faster than JoMa1-ALK-R1275Q and 
JoMa1-ALK-wt bearing mice (p<0.02), while no tumor 
was found in mice implanted with JoMa1 or JoMa1-Migr 
control cells (Figure 3A). Exogenous ALK expression 
in orthotopic tumors was confirmed by RT-PCR, WB 
and IHC, while murine Alk was undetected (Figure 3B, 
and Supplementary Figure 3). Ki67 labeling revealed an 
enhanced proliferation index in JoMa1-ALK-F1174L-
derived tumors (48%) compared to JoMa1-ALK-R1275Q- 
(40%), and JoMa1-ALK-wt-derived tumors (38%) (Figure 
3b), suggesting that the accelerated tumor growth of 
JoMa1-ALK-F1174L tumors may partly result from their 
increased proliferation capacity. 
Subcutaneous and orthotopic JoMa1-ALK-derived 
tumors correspond to highly malignant undifferentiated 
tumors (Figure 2E, and 3B), Phox2b-/Th-, but strongly 
expressing CD44, nestin, and weakly Ncam1 (Figure 3C). 
Tumors histologically close to NB, such as Ewing tumors, 
melanoma, or lymphoma were excluded, as their specific 
markers (CD99, Tyr, and Ptprc (CD45), respectively) 
were not detected (Figure 3C). Hence, JoMa1-ALK-wt, 
-F1174L, -R1275Q cells, similarly to MONC-1-ALK-
F1174L cells, gave rise to undifferentiated NC cell-derived 
tumors.
Activation of ALK downstream signaling pathways 
analyzed in orthotopic tumors revealed phosphorylation of 
AKT, ERK and Stat3 in JoMa-ALK-F1174L tumors, while 
JoMa1-ALK-R1275Q tumors preferentially activated 
PI3K/AKT and Stat3 pathways, and JoMa1-ALK-wt 
tumors strongly activated PI3K/AKT and ERK pathways, 
while only weakly the Stat3 pathway (Supplementary 
Figure 4).
To further characterize JoMa1-ALK orthotopic 
tumors, their global gene expression profiles were 
analyzed using Affymetrix murine 430.2 arrays, and 
compared to transcriptomes of murine NB derived from 
TH-NMYC, ALKF1174L/DBHHiCre, and TH-NMYC/
ALKF1174L/DBHHiCre transgenic models and adrenal 
glands previously analyzed by Heukamp et al. [23], as 
Figure 4: Tumor-derived cell lines become independent of Myc-ERT activity, but remain dependent of ALK activity. 
Clonogenic assays in methylcellulose with parental and t.d JoMa1-ALK cells incubated for 2 weeks in absence or presence of 4-OHT (200 
nM), and/or TAE684 (1uM). One representative methylcellulose assay is shown. 
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well as to transcriptome of JoMa1 cells and cell lines 
established from JoMa1-NMYC-derived tumors (mTu3-
6) described by Schulte et al. [22], using the same 
Affymetrix arrays. Clustering results revealed that the 
three groups of JoMa1-ALK (F1174L, R1275Q, and wt) 
orthotopic tumors clustered together and close to JoMa1 
and JoMa1-NMYC derived tumors cell lines, as well as to 
adrenal glands, while NB derived from murine transgenic 
models were much more distant (Supplementary Figure 
5). This confirms that our orthotopic JoMa1-ALK-derived 
tumors were significantly different from murine NB 
models. This also indicates that variations found between 
JoMa1-ALK tumors and NB transgenic models did not 
result from differences between experimental procedures, 
as all JoMa1 samples (ours and those of Schulte et al.) 
clustered together (Supplementary Figure 5). Analyses of 
differentially regulated genes (FC>3 and p<0.05) revealed 
1634 upregulated, and 1493 downregulated genes in 
orthotopic JoMa1-ALK tumors compared to transgenic 
NB tumors. Interestingly, various NCSC or SC associated 
markers, such as Myc, Sox2, Sox9, Notch1, Notch2, 
Snai2, Bmp1/2, Twist1/2, Hmga2, nestin, and vimentin 
were identified among the upregulated genes (Table 1), 
while sympathoadrenal lineage markers (Phox2a, Phox2b, 
Gata2, Gata3, Th, and Dbh), neuroendocrine markers 
(Chromogranin A, synaptophysin), neuronal markers 
Figure 5: Myc expression is strongly enhanced in orthotopic tumors and in tumor-derived cell lines, and plays a strong 
oncogenic role in vitro. A. Myc mRNA expression levels measured by semi-quantitative real-time qPCR in parental JoMa1 cells and 
in orthotopic tumors. Five representative samples were analyzed for JoMa1-ALK-F, and JoMa1-ALK-R tumors; 4 for JoMa1-ALK-wt 
tumors, t.d.JoMa1-ALK-F, and t.d.JoMa1-ALK-R cell lines; and 3 for t.d.JoMa1-ALK-wt cell line. To note: the exogenous Myc-ERT is 
from human origin and was not detected by the murin Myc specific primers used. Mean ratio between Myc and β-actin as measured in 
three independent experiments are indicated (*=p<0.05, and **=p<0.005). B. Myc mRNA expression levels in orthotopic tumors, and in 
t.d.JoMa1 cell lines measured as in A (*=p<0.02, ***=p<0.005, and ***=p<0.0005). C. Mycn mRNA expression levels measured as in A. 
D. Myc and Mycn mRNA expression levels in ALK-F parental and t.d. cell lines treated or not with 1 µM TEA684 for 24h, and measured as 
in A (see different scales)(*=p<0.05, **=p<0.002). E. Pictures of one representative clonogenic assay in methylcellulose are shown. Cells 
were incubated for 2 weeks in absence or presence of 80uM Myc inhibitor (10058-F4). 
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(Neurofilament, Ncam1, and Uchl1) and Mycn were 
present in the downregulated genes (Table 1, and Figure 
3D). These results confirm that in our NCPC model, ALK-
wt or activating ALK variants drive the formation of 
highly undifferentiated NC cell-derived tumors, and may 
even impair NB tumor differentiation. 
Tumor-derived JoMa1-ALK cells display an 
enhanced oncogenic potential compared to their 
parental cells
To further analyze tumorigenic properties of 
orthotopic tumor cells, cell lines were established upon 
tumors dissociation, which became independent of 
Myc-ERT activity for long term passages in vitro. The 
clonogenic properties of t.d.JoMa1-ALK cell lines 
were then analyzed by semi-solid clonogenic assays in 
methylcellulose. T.d.JoMa1-ALK cell lines were able 
to produce numerous and large colonies in absence of 
4-OHT, and addition of 4-OHT did not significantly 
increase colony number, or colony size, confirming their 
independency to Myc-ERT activity, in contrast to parental 
cells, which were only able to form few macroscopic 
colonies in presence of 4-OHT (Figure 4). Furthermore, 
TAE684-mediated ALK inhibition completely abolished 
the clonogenic potential of t.d-JoMa1-ALK cell lines 
even in presence of 4-OHT (Figure 4), indicating that 
t.d-JoMa1-ALK cells display an enhanced oncogenic 
potential compared to their parental cells, but remained 
fully dependent on ALK activity.
ALK mediates Myc upregulation in JoMa1-ALK 
tumors and tumor-derived cell lines, and both 
oncogenes cooperate in the oncogenic process.
Myc was found to be overexpressed in JoMa1-
derived tumors compared to NB transgenic models, 
while Mycn was downregulated (Table 1). To validate 
these data, Myc and Mycn mRNA expression levels were 
measured in JoMa1-ALK tumors and in their respective 
parental or tumor-derived cell lines. Myc was upregulated 
in transduced JoMa1-ALK-F1174L and -ALK-R1275Q 
cells relative to JoMa1-Migr control cells (Supplementary 
Figure 6A). In addition, Myc mRNA expression level was 
increased in orthotopic and subcutaneous tumors compared 
to their respective parental JoMa1-ALK cells (Figure 5A, 
and Supplementary Figure 6B). Moreover, Myc was also 
significantly upregulated in t.d.cell lines as compared to 
their tumors of origin (Figure 5B). Furthermore, JoMa1-
ALK-F1174L tumors, or t.d.JoMa1-ALK-F1174L cells, 
expressed significantly higher amounts of Myc mRNA 
compared to JoMa1-ALK-R1275Q- and JoMa1-ALK-wt-
derived tumors, or -associated t.d.cell lines, respectively 
(Figure 5A, 5B, and Supplementary Figure 6B). Finally, 
qPCR analyses confirmed the particularly weak Mycn 
mRNA expression levels in JoMa1-ALK orthotopic 
tumors and t.d.cell lines relative to Myc levels (Figure 5C 
and B, see the different scales). However, Mycn mRNA 
expression was superior in JoMa1-ALK-F1174L tumors 
relative to JoMa1-ALK-R and JoMa1-ALK-wt tumors 
(Figure 5C). Altogether, these results suggest that Myc, 
rather than Mycn, may have an essential role in the 
tumorigenesis of ALK-expressing JoMa1 cells in vivo.
To further investigate whether Myc upregulation 
observed in t.d.cells was dependent on ALK activity, 
tumor-derived and parental JoMa1 cells were treated 
with the ALK inhibitor TAE684 for 24h. Myc mRNA 
expression was strongly downregulated upon TAE684 
treatment (Figure 5D, and data not shown for t.d.JoMa1-
ALK-R and -ALK-wt cells). Interestingly, Mycn mRNA 
expression levels were inversely correlated to that of Myc, 
as Mycn was strongly upregulated in presence of TAE684, 
even if the Mycn/β-actin ratio remained extremely low 
compared to that of Myc (Figure 5D). 
To analyze whether Myc upregulation participated 
to the increased tumorigenicity of t.d.JoMa1 cell lines, 
we measured their clonogenic capacity in presence or 
absence of the Myc inhibitor 10058-F4. Interestingly, in 
vitro tumorigenic capacities of t.d.JoMa1-ALK expressing 
cells were completely abolished by treatment with 10058-
F4 (Figure 5E, and data not shown for t.d.JoMa1-ALK-wt 
cells). Overall these results suggest that Myc cooperate 
with ALK-F1174L, as well as with ALK-R1275Q and 
ALK-wt, in enhancing the clonogenic capacities of tumor-
derived cells in vitro and possibly tumor growth in vivo.
DISCUSSION 
The role of ALK-wt, ALK-F1174L and ALK-
R1245Q in NB tumor initiation was investigated in 
two NCPC models, MONC-1 and JoMa1. We have 
demonstrated by orthotopic implantations in mice that 
parental MONC-1 cells produced diverse tumor types, 
such as undifferentiated NB, osteo-chondrosarcoma, and 
undifferentiated tumors, recapitulating the pluripotency of 
MONC-1 NCPC. Interestingly, ALK-F1174L expression 
in MONC-1 cells not only strongly accelerated tumor 
growth, but also affected their differentiation capacity. 
Indeed, MONC-1-ALK-F1174L cells only developed 
highly malignant undifferentiated tumors expressing high 
levels of the neural stem/progenitor cell marker nestin. 
Similarly, we provide the first demonstration that even in 
absence of exogenous Myc-ERT activity, ALK-wt, ALK-
F1174L, or ALK-R1275Q expression in NCPC JoMa1 are 
sufficient to initiate highly aggressive, undifferentiated 
tumor formation, although not to drive NB progression. 
We have shown that MONC-1-ALK-F1174L- and 
JoMa1-ALK-derived tumors were nestin+ and Phox2b-. 
Interestingly, hyperplastic lesions observed in early post-
natal sympathetic ganglia derived from TH-MYCN NB 
mice models contained nestin+/Phox2b- cells. These cells 
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were proposed to “represent a population of malignant 
sympathetic neural crest or early progenitor cells that give 
rise to Phox2b positive tumor cells comprising the bulk 
of NB tumors” [31, 32]. Thus, ALK expressing MONC-
1- and JoMa1-derived tumors may correspond to such 
malignant NCPC populations. 
Comparison of gene expression profiles between 
orthotopic JoMa1-ALK-derived tumors and NB transgenic 
mouse models of Heukamp et al. [23] revealed a strong 
upregulation of SC- or NCSC-associated markers, and 
a significant downregulation of differentiation markers 
related to neuronal or sympathoadrenal lineage in JoMa1-
ALK-derived tumors. Thus, in our NCPC models, ALK 
expression in MONC-1 or JoMa1 cells appeared to 
maintain tumor cells in an undifferentiated state. The 
high Myc/Mycn ratio detected in our orthotopic tumors 
may partly explain their stem-like phenotype, as Myc is 
one of the few genes needed to induce pluripotent stem 
cell reprogramming [33]. Although produced in the 
same JoMa1 model, our results differ from Schulte et al. 
report, which show only a very weak tumorigenic and 
NB-inducing potential of JoMa1-ALK-F1174L cells after 
subcutaneous injection [22]. The selection of clones in 
Schulte study and variations in ALK-F1174L expression 
levels in JoMa1 cells are elements that could explain the 
discrepancies between both studies. 
Understanding of mechanisms responsible for ALK-
mediated inhibition of NCPC differentiation will require 
further investigations. NB tumors expressing activated 
ALK derived from MYCN/KI ALK mice displayed a more 
differentiated phenotype as compared to MYCN tumors 
derived from TH-MYCN mice [26]. ALK was also shown 
to induce differentiation of PC12 cells by inducing neurite 
outgrowth [34]. However, membrane attachment of ALK-
tyrosine kinase domain was shown to be crucial for the 
control of neurite outgrowth and proliferation arrest, while 
cytoplasmic localization promoted cell proliferation [34]. 
Thus, ALK cellular localization may play a role in the 
switch between proliferation and differentiation. It should 
be noted that ALK localization in MONC-1- and JoMa1-
ALK tumors was mostly cytoplasmic. Interestingly, ALK 
expression was recently shown to be associated with less 
differentiated neuroblastic tumors, as the frequency of 
ALK positivity in NB was significantly higher than in 
ganglioneuroblastoma, and in ganglioneuroma [35, 36]. 
Observations that frequent ALK-wt overexpression 
in NB primary tumors was associated with poor clinical 
outcome, similarly to activating ALK mutations [10, 
17, 18, 37], suggested that ALK-wt overexpression may 
be involved in NB oncogenesis and progression. We 
demonstrate here for the first time that ALK-wt expression 
in NCPC JoMa1 can drive malignant tumor formation in 
nude mice. Until this study, ALK-wt transforming capacity 
could not be demonstrated neither in clonogenic assays 
nor upon subcutaneous implantations [13, 14, 38, 39]. 
Also, ALK-wt expression was unable to cooperate with 
MYCN in inducing NB formation in a zebrafish NB model 
[25]. These negative results may be explained by ALK-wt 
protein expression levels, which probably did not reach 
the critical threshold necessary for ALK-wt oncogenic 
autoactivation [40], while here we were able to detect a 
weak constitutive ALK phosphorylation in transduced 
JoMa1-ALK-wt cells. 
The capacity of activating ALK mutations or 
ALK-wt overexpression to initiate tumor formation 
and progression may be dependent on their expression 
levels, as discussed above, as well as on their temporal 
expression during sympathetic neuronal development 
and differentiation. The production of a Tamoxifen-
dependent Cre model allowing ALK activation at different 
development time points, as suggested [23], could help to 
determine whether a specific development period exists 
for NB tumor initiation and progression. Here, ALK was 
expressed in NCPC, which represent a very early stage of 
NC cell differentiation, as compared to ALK expression 
driven by Th or Dbh promoters in NB transgenic 
models. Indeed, Th and Dbh are expressed later in more 
differentiated cells of the sympathoadrenal lineage during 
noradrenergic induction of sympathetic neurons [1, 4]. The 
bona fide model to study the exact role of ALK mutations 
in NB tumor initiation and progression is the generation 
of ALK KI mutants, as recently described by Janoueix-
Lerosey et al. [26]. In this study, the KI of the murine 
equivalents (ALK-F1178L and R1279Q in mice) of the 
two most frequent ALK activating mutations in patient 
were generated. ALK KI mice displayed in an enlargement 
in sympathetic ganglion resulting from enhanced 
proliferation of sympathetic neuroblasts [26]. However, 
expression of activating mutants did not generate tumors 
in mice in absence of MYCN expression, confirming 
that activated Alk was not sufficient to drive neuroblastic 
tumors [26]. 
So, our NCPC JoMa1 model revealed the strong 
tumor-initiating capacity of ALK-wt and activating 
mutants, in contrast to NB murine models. Indeed, in 
zebrafish and murine NB transgenic models, ALK-
F1174L expression driven by Dbh or Th promoter, as well 
as activated ALK KI mutants, did not allowed to confer 
a fully transformed phenotype to NC derived cells, and 
thus to induce tumor formation, while co-expression of 
MYCN was required for NB development [24, 25, 26]. 
Also, ALK-F1174L required additional hits to drive NB 
development in the conditional actin-ALKF1174L;DBH-
HiCre transgenic mouse model of Heukamp et al., as NB 
tumors occurred only in presence of additional genetic 
alterations [23]. Thus, ALK was not sufficient to drive NB 
formation both in NB murine models, and in our NCPC 
model.
We also confirmed the previously described 
remarkable tumorigenic potential of ALK-F1174L 
mutation [10, 13, 20-22, 38] in our NCPC MONC-1 and 
JoMa1 models. This can be in part be explained by the 
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higher proliferation index of JoMa1-ALK-F1174L tumors. 
The enhanced tumorigenic potential of ALK-F1174L in 
the JoMa1 model may also be explained by the stronger 
upregulation of Myc in JoMa1-ALK-F1174L tumors 
compared to JoMa1-ALK-R1275Q and JoMa1-ALK-wt 
tumors. Increased Myc expression was also observed in all 
JoMa1-ALK tumors and tumors-derived cell lines, when 
compared to parental JoMa1-ALK cells. This may result 
from the in vivo selection of cells displaying enhanced 
survival and proliferation capacities. We demonstrated 
that Myc upregulation was predominantly dependent on 
ALK activity, as treatments of tumor-derived JoMa1-
ALK-expressing cells with TAE684 induced strong 
downregulation of Myc mRNA. In addition, expression 
of activating ALK mutants in JoMa1 transduced cells 
upregulated Myc compared to control JoMa1-Migr 
cells. Upregulation of Myc was previously described in 
NMP/ALK-positive compared to NMP/ALK-negative 
lymphoma [41], suggesting that Myc may be an important 
downstream target of ALK signaling. The preferential 
ALK-mediated induction of Myc over Mycn, observed in 
our NCPC model as opposed to neuronal and NB cells 
[21, 24], may result from ALK expression in different 
developmental stages of NC-derived cells, which may 
express distinct stage-determining factors. In NB, Myc 
expression was shown to predominate over MYCN 
when both genes are expressed in absence of MYCN 
amplification or forced overexpression [42]. Conversely, 
Myc seems to be repressed by MYCN in MYCN-amplified 
NB, indicating regulatory interaction between Myc 
and MYCN expression [42]. Indeed, we observed that 
Myc mRNA downregulation, induced by ALK inhibitor 
treatment in tumor-derived JoMa1-ALK cells, was 
concomitant with Mycn upregulation. Thus, ALK-wt 
and activating mutants may not only upregulate MYCN 
mRNA expression, as shown in neuronal and NB cells 
[21], and cooperate with MYCN in NB tumorigenesis 
[21, 23-25], but they may also upregulate and cooperate 
with Myc, as observed in murine NCPC. Interestingly, the 
tumorigenic potential of t.d.-JoMa1-ALK expressing cells 
was strongly dependent on both ALK and Myc activities, 
as ALK or Myc inhibitor completely impaired their in 
vitro clonogenic potentials.
Therefore, our NCPC models allowed us to 
demonstrate the role of ALK-wt and the most frequent 
activating ALK mutations in NCPC in tumor initiation 
and in differentiation control. These models may also be 
valuable in the further identification of ALK-mediated 
mechanisms in oncogenesis.
MATERIALS AND METHODS
Culture of MONC-1 and JoMa1 cells
MONC-1 and JoMa1 cells were maintained in an 
undifferentiated state using the NC culture medium (NCC-
medium [29]), supporting NCPC proliferation, composed 
of Dulbecco’s Modified Eagle Medium (DMEM) F-12 
(Invitrogen), 1% N2-Supplement (Invitrogen), 2% B27-
Supplement (Invitrogen), 10 ng/ml EGF (R&D), 4 ng/
ml FGFβ (PeproTech), 1% Penicillin-Streptomycin 
(Invitrogen), and 10% Chicken-Embryo-Extract [43]. 
Cells were cultivated in fibronectine coated dishes (1mg/
ml, Sigma-Aldrich). For Myc-ERT activation, 200 nM 
4-OHT (Sigma-Aldrich) was added to NCC-medium.
Retroviral infections
ALK cDNA XhoI-EcoRI fragments, isolated from 
ALK-wt-, ALK-F1174L-, and ALK-R1275Q-pcDNA3 
constructs [44] were introduced into XhoI-EcoRI sites 
of the biscistronic retroviral vector pMigr1 encoding for 
eGFP [45]. All ALK-expressing vectors were verified by 
DNA sequencing. Retroviral infection were performed as 
described previously [46], and GFP+ cells sorted by FACS 
Aria Cell Sorter (Becton Dickinson). After expansion, 
transduced cells were frozen, and in vitro or in vivo assay 
were performed with only early cell passages.
RNA preparation and RT-PCR
Total RNA from cell lines and tumors were 
extracted using RNeasy or miRNeasy Mini kits (Qiagen), 
respectively. CDNA were prepared as described earlier 
[47]. PCR using GoTaq Hot Start Kit (Promega) 
were performed with following primers: Ngfr-for 
5’-GAATGCGAGGAGATCCCTGG-3’, Ngrf-rev 
5’-GGAGCAATAGACAGGAATGAGG-3’, Snai1-
for 5’-CACCCATACAGGTGAGAAGC-3’, Snai1-
rev 5’-TGTCCTGGATGACAGAACCA-3’, Nefh-for 
5’-GCAGCCAAAGTGAACACAGA-3, Nefh-rev 
5’-CTGAATAGCGTCCTGGTAGG-3’, Mash1-for 
5’-TTGAACTCTATGGCGGGTTC-3’, Mash1-rev 
5’-GCCATCCTGCTTCCAAAGTC-3’, human ALK-for 
5’-TGTTGCCTCTCCTCGATGTG-3’, human ALK-
rev TGTCTTCTCCGCTAATGGTG-3’, murine Alk-for 
5’-TGCCAGAAGTGTGTTCAGAAC-3’, murine Alk-rev 
5’-CCCTTCCATGAAGGCTTCAG-3’. Primers for Snai2, 
Sox9, Sox10, Gfap, Gapdh were described [29]. Cycling 
reactions were 2min at 95°C followed by 35 cycles of 30s 
at 95°C, 30s at 60 to 65°C and 30s at 72°C, followed by 
5min at 72°C. 
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Real-Time qPCR
Expression levels of Myc, Mycn, and β-actin were 
assessed by semi-quantitative real-time qPCR as described 
[47] with the QuantiFast SYBR® green kit (Qiagen) and 
primers specific for murine Myc, Mycn, and β-actin 
(QuantiTect primer assay, Qiagen). Cycling conditions 
were 5min at 95°C, 40 cycles of 10s at 95°C, 20s at 60°C, 
and 1s at 72°C. Ratio of Myc or Mycn to β-actin gene 
expression was evaluated using the ∆Ct method.
Immunoblotting
JoMa1 cells were lysed in 10 mM Tris-Hcl (pH 7.4), 
150 mM NaCl, 5 mM EDTA, 25 mM β-glycerophosphate, 
10% glycerol, 1% NP40, 0.25 % Na-deoxycholate, 20 
mM NaF, 1 mM Na-pyrophosphate, 1 mM Na3VO4 and 1x 
protease inhibitor. Cell lysates were sonicated three times 
for 10 sec, and centrifugated at 13’000 rpm at 4°C during 
30 min. Phosphoproteins were detected using polyclonal 
rabbit antibodies specific for phospho-ALK (pTyr1604, 
AssayBioTech), phospho-AKT (Cell Signaling), phospho-
STAT3 (Cell Signaling) or phospho-ERK (Cell Signaling). 
Membranes were stripped 10min at 50°C in 2% SDS, 65.5 
mM Tris-HCL pH 6.8 and 100 mM β-mercaptoethanol, 
and total protein expressions were detected using 
polyclonal rabbit antibodies specific for ALK (Invitrogen), 
AKT (Cell Signaling), STAT3 (Cell Signaling), or ERK 
(Cell Signaling).
Methylcellulose clonogenic assay
JoMa1 cells (1.3*103) were grown in 500 µl semi-
solid medium [53% methylcellulose (Fluka, and prepared 
as in [48]), 17% FCS (Sigma), 30% DMEM (Gibco), 
and Penicilin-Streptomycin] in PolyHema (poly-2-
hydroxyethyl-methacrylate, 16 mg/ml in EtOH, Sigma)-
coated 24-well culture plates, to prevent cell adhesion. 
Tamoxifen (200nM), TAE684 (1µM) or 10058-F4 (80µM) 
were added twice a week in 100μl DMEM complemented 
with 10% FCS and Penicillin-Streptomycin. After 2 
weeks, colonies were counted using an optic microscope, 
stained with a mix of 50% MTS/PMS (Promega) and 50% 
DMEM (Gibco) during 2 hours, and pictures were taken 
with AlphaImager®.
In vivo studies
All animal experiments were carried out with 
female, athymic Swiss nude mice (BALB/C nu/nu), 4-6 
weeks of age purchased from Charles River in accordance 
to the European Community guidelines (directive no. 
86/609/CEE) as described [49, 50]. In subcutaneous 
model, 5x105 cells were injected in both flanks of mice 
(3 per group). In orthotopic model, 10, or 7 mice per 
groups were injected in left AG with 105 MONC-1 cells, 
or 1.5x105 JoMa1 cells, respectively, resuspended in 10 μl 
of PBS. Abdominal incisions were closed with skin clips.
Tumor take and growth were followed up using 
calipers twice a week for subcutaneous injections or by 
ultrasound every 3, 7, or 14 days according to tumor 
progression. Subcutaneous or orthotopic tumor volumes 
were calculated using the formula (length×width2)/2, 
or 4/3×π×(depth×sagittal×transversal)/6 formula, 
respectively. Mice with tumor volumes greater than ~1000 
mm3, or ~800 mm3 were sacrificed for subcutaneous, or 
orthotopic injections, respectively. Every tumor was split 
into pieces for paraffin-embedded tissue formation, RNA 
or protein extraction, or cell dissociation. 
Tumor dissociation and establishment of tumor-
derived cell lines
Cells were dissociated from orthotopic tumors as 
described earlier [51] and propagated like parental cells. 
Tumor-derived cell purity was analyzed after 2 weeks by 
flow cytometry for GFP expression.
Immunohistochemistry
All immuno-labeling were performed by the 
Lausanne Mouse Pathology Facility. Hematoxylin and 
eosin (H&E) staining was performed on all subcutaneous 
and orthotopic tumors. Immunohistochemistry (IHC) 
was performed using mouse monoclonal Ab anti-TH 
(MAB318, Millipore), rabbit polyclonal Ab anti-ALK (51-
3900, Invitrogen), anti-Tyr (a gift from Bhushan Sarode, 
EPFL), anti-CD99 (Orb13719, Biorbyt), anti-Ncam1 
(14255-1-AP, Proteintech), rat monoclonal Ab anti-CD44 
(550538, BD Pharmingen), anti-Ptprc (CD45) (550539, 
BD Pharmingen), anti-nestin (MAB353, Millipore), anti-
Ki67 (M7249, DAKO), anti-Phox2b (H-20, Santa Cruz 
Biotechnology).
Ki67 proliferation index was determined by 
analyzing 5 fields imaged at 40x magnification per tumor 
section in 4 different tumors from each group. Sections 
were imaged using a Zeiss Axio LabA1 microscope and 
Axiovision Rel. 4.5 imaging software. 
Microarray analyses
CDNA, prepared from total RNA of orthotopic 
tumors, were hybridized to the Affimetrix GeneChip® 
Murine 430.2 oligonucleotide Array according to 
manufacturer’s instructions. Arrays were normalized by 
the GCRMA procedure using Brainarray annotations [52].
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Statistical analysis
Statistical significance of results was analyzed using 
t-test and one-way ANOVA analysis using GraphPad 
Prism 5.04 software (GraphPad Software, Inc.).
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